Sorrento Therapeutics Inc (SRNE)

Sorrento Therapeutics, Inc. is a common stock listing on OTC Markets tied to a healthcare company focused on biotechnology. The company has described itself as a clinical and commercial stage biopharmaceutical business serving markets in the United States and internationally. Its programs have included cell therapies such as chimeric antigen receptor T-cell and dimeric antigen receptor T-cell therapies, antibody-drug conjugates, and assets including Seprehvec, SOFUSA, RTX, and SEMDEXA. Sorrento has also worked on antiviral therapies, vaccines, and diagnostic test solutions for applications in cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. Founded in 2006 and based in San Diego, California, the company and an affiliate filed for Chapter 11 reorganization in February 2023, and the case was later approved as Chapter 11 liquidation in November 2023.

Jump directly to the stock analysis sections supported by the latest available data.